Odanacatib Phase III Success Suggests Merck’s Primary Care Gamble Is Paying Off
This article was originally published in Pharmaceutical Approvals Monthly
A data monitoring committee’s early termination of a 16,000-patient Phase III study of Merck’s cap-K inhibitor odanacatib suggests the osteoporosis therapy could have a competitive profile. The drug will need to offer significant advantages to cut it in the crowded market already saturated with generics.
You may also be interested in...
Two of Merck’s potential near-term launches, suvorexant for insomnia and odanacatib for osteoporosis, will enter crowded markets dominated by generics, but executives at the Citi Global Health Care conference maintain that novel mechanisms of action will address unmet market opportunities.
Merck announced its potential first-in-class dual orexin receptor antagonist suvorexant successfully completed a second Phase III trial, apparently without safety concerns that led Actelion/GlaxoSmithKline to drop their DORA almorexant a year ago on Phase III results.